Studying the Renoprotective Effects of Dapagliflozin in type 2 diabetes

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve hard renal outcomes in type 2 diabetes. This is possibly explained by the fact that SGLT2i normalize the measured glomerular filtration rate (mGFR) by increasing renal vascular resistance, as was shown in young people with type 1 diabetes and glomerular hyperfiltration. Therefore, we compared the renal hemodynamic effects of dapagliflozin with gliclazide in type 2 diabetes. The mGFR and effective renal plasma flow were assessed using inulin and para-aminohippurate clearances in the fasted state, during clamped euglycemia (5 mmol/L) and during clamped hyperglycemia (15 mmol/L).

Source: Kidney International - October 9, 2019 Category: Urology & Nephrology Authors: Erik JM. van Bommel, Marcel HA. Muskiet, Micha ël JB. van Baar, Lennart Tonneijck, Mark M. Smits, Anna L. Emanuel, Andrea Bozovic, A.H. Jan Danser, Frank Geurts, Ewout J. Hoorn, Daan J. Touw, Emil L. Larsen, Henrik E. Poulsen, Mark HH. Kramer, Max Nieuwd Tags: Clinical Trial Source Type: research